Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Strategic Alliance Partners
Latest from Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Closing Thoughts on the MDS Treatment Landscape
March 26, 2024
Video
Following its comprehensive discussion on the treatment of MDS, the expert panel concludes with thoughts on the overall treatment landscape.
Takeaways from ASH 2023 in Higher-Risk MDS
March 19, 2024
Video
Experts on myelodysplastic syndromes offer their key takeaways from the 2023 ASH Annual Meeting in the higher-risk disease space.
Updates from ASH 2023 in Higher-Risk MDS
March 19, 2024
Video
Hematologist-oncologists review clinical trial data updates presented at ASH 2023 in higher-risk MDS.
Treatment Options and Unmet Needs in Higher-Risk MDS
March 12, 2024
Video
Comprehensive insights on the current treatment landscape and remaining unmet needs for patients with higher-risk MDS.
Emerging Clinical Trials in MDS and Key Takeaways from ASH 2023
March 12, 2024
Video
The panel discusses emerging clinical trials in the MDS treatment space and offers key takeaways from the 2023 ASH Annual Meeting.
Cytopenias Following Imetelstat Treatment in Lower-Risk MDS
March 05, 2024
Video
An MDS specialist discusses cytopenias associated with imetelstat treatment in patients with lower-risk MDS, highlighting findings from the IMerge clinical trial.
IMerge: Imetelstat in Patients With Lower-Risk MDS
March 05, 2024
Video
The expert panel discusses abstracts surrounding the IMerge clinical trial on imetelstat in patients with lower-risk myelodysplastic syndromes.
Levy Delves Into the Evolution of ADCs in NSCLC
March 04, 2024
Article
Benjamin Philip Levy, MD, discusses lingering questions regarding the use of antibody-drug conjugates in lung cancer.
Retrospective Claims Data and Patient Reported-Outcomes from COMMANDS Trial in Lower-Risk MDS
February 27, 2024
Video
Amy DeZern, MD, MHS, discusses a retrospective study on healthcare claims for patients with MDS treated with luspatercept and reviews patient-reported outcomes from the COMMANDS trial.
Updates from COMMANDS Trial: Luspatercept in Lower-Risk MDS
February 27, 2024
Video
Following ASH 2023, Andrew Brunner, MD, reviews key updates from the COMMANDS trial investigating frontline luspatercept in patients with lower-risk MDS.
Tackling All Questions ADC: How These Agents Are Joining a Treatment Revolution in NSCLC
February 26, 2024
Article
Benjamin Philip Levy, MD, details how antibody-drug conjugates are shifting the HER2-mutated non–small cell lung cancer treatment paradigm.
ESA Treatment Selection in MDS
February 20, 2024
Video
Clinical insights on selecting appropriate erythropoiesis-stimulating agents in patients with myelodysplastic syndromes.
Unmet Needs and Adverse Event Management for Patients With Lower-Risk MDS and Symptomatic Anemia
February 20, 2024
Video
Hematologist-oncologists address adverse event management and discuss the unmet needs of patients with lower-risk MDS and symptomatic anemia.
Patient Profile 2: A 77-Year-Old Man With MDS
February 14, 2024
Video
The expert panel provides comprehensive insights on another patient case, a 77-year-old with MDS who presented with symptomatic anemia.
Second-Line Treatment of Lower-Risk MDS With Symptomatic Anemia
February 14, 2024
Video
Continuing their discussion on the first patient profile, the expert panel focuses on the second-line treatment of patients with lower-risk MDS and symptomatic anemia.
Continued ADC Development in NSCLC Necessitates Improved Knowledge of Mechanisms and Biomarker Optimization
February 07, 2024
Article
Identifying biomarkers and the mechanism of action of antibody-drug conjugates may optimize benefits with these agents in non–small cell lung cancer.
Patient Profile 1: A 72-Year-Old Man With MDS
February 06, 2024
Video
Andrew Brunner, MD, presents the profile of a 72-year-old man with MDS and the panel offers their initial impressions on the case, focusing on the treatment decisions.
First-Line Treatment of Lower-Risk MDS with Symptomatic Anemia
February 06, 2024
Video
Amy DeZern, MD, MHS, provides clinical insights on the first-line treatment of patients with lower-risk MDS and symptomatic anemia.
Dr Levy on Unanswered Questions Regarding the Mechanism of Action of ADCs in NSCLC
February 03, 2024
Video
Benjamin Levy, MD, discusses the mechanism of action of antibody-drug conjugates in patients with non–small cell lung cancer.
Risk Stratification of Myelodysplastic Syndromes
January 30, 2024
Video
Hematologist-oncologists discuss the risk stratification of patients with myelodysplastic syndromes and how patient risk status determines prognosis.